Has Vinay Tumuluri, MD received payments from drug or device companies?

Yes. Drug and device makers reported $23,042 in general payments to Vinay Tumuluri, MD across 1,458 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Vinay Tumuluri, MD did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Vinay Tumuluri, MD come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Vinay Tumuluri, MD

Internal Medicine · la Porte, INNPI 1528015344

Payments from drug & device makers

$23,042in general payments, 2019–2025

Across 1,458 payments — averaging $15.80 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

AbbVie$3K
Novo Nordisk$2K
Amgen$1K
Pfizer$1K
Boehringer Ingelheim$1K
AstraZeneca$1K
plus $14K from 54 others

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
AbbVie(2 entities)	194	$2,629
Novo Nordisk	123	$1,630
Amgen(2 entities)	61	$1,283
Pfizer	94	$1,225
Boehringer Ingelheim	75	$1,213
AstraZeneca	67	$1,202
Lilly USA, LLC	73	$1,171
Merck	58	$850
Bayer	45	$822
GSK	68	$801
Novartis	47	$707
Sanofi-aventis U.S. LLC	34	$674
Johnson & Johnson	64	$523
Mylan Specialty L.p.	24	$491
Takeda Pharmaceuticals U.S.A., Inc.	30	$420
Corium, LLC	18	$403
Almatica Pharma LLC	24	$371
Otsuka America Pharmaceutical, Inc.	19	$353
Axsome Therapeutics, Inc.	14	$341
Dexcom, Inc.	18	$308
Astellas Pharma US Inc	17	$298
Amarin Pharma, Inc.	26	$282
Boston Scientific	2	$267
Corcept Therapeutics	14	$253
Biohaven Pharmaceutical Holding Company Ltd.	14	$247
Vanda Pharmaceuticals Inc.	7	$243
Kowa Pharmaceuticals America, Inc.	18	$233
Biohaven Pharmaceuticals, Inc.	12	$229
Sunovion Pharmaceuticals Inc.	17	$225
Insulet Corporation	13	$186
Sumitomo Pharma America, Inc.	12	$186
ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)	9	$165
Viatris Specialty LLC	9	$158
Salix Pharmaceuticals, A Division Of Bausch Health US, LLC	10	$149
Antares Pharma, Inc.	8	$148
Supernus Pharmaceuticals, Inc.	8	$142
Phathom Pharmaceuticals, Inc.	8	$135
ANI Pharmaceuticals, Inc.	1	$125
Lexicon Pharmaceuticals, Inc.	1	$123
Alkermes, Inc.	6	$111
Jazz Pharmaceuticals Inc.	6	$108
Xeris Pharmaceuticals, Inc.	6	$106
Edwards Lifesciences	3	$101
Lundbeck LLC	5	$99
E.r. Squibb & Sons, L.L.C.	7	$97
Idorsia Pharmaceuticals US Inc	6	$97
Vertex	5	$92
Exact Sciences	5	$91
Abbott	6	$89
Esperion Therapeutics, Inc.	4	$84
Ironwood Pharmaceuticals, Inc	5	$73
Shield Therapeutics Inc	2	$66
Teva Pharmaceuticals USA, Inc.	4	$65
Radius Health, Inc.	3	$63
Paratek Pharmaceuticals, Inc.	3	$58
Ardelyx, Inc.	3	$51
Neurocrine Biosciences, Inc.	3	$51
Eisai Inc.	3	$46
Biogen	2	$43
Alnylam Pharmaceuticals Inc.	2	$43

How this compares

$23,042 in reported general payments places this provider in the 95th percentile of 1,747 internal medicine providers in Indiana.

See all internal medicine providers in Indiana →

Medicare billing

Part B allowed, 2024

$305,821

Medicare patients

718

Services billed

3,970

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other internal medicine in la Porte

Joseph Arulandula Porte$251K
Robert BuynakValparaiso$24.2M
Mohammed AllawNewburgh$3.6M
Raj VuppalanchiIndianapolis$3.4M
Phillip TothIndianapolis$3.2M
George CornettFranklin$1.3M
Ajita NarayanLafayette$951K
Abhinav SinghGreenwood$738K
Georgiann LinnemeierIndianapolis$692K
Wa'el BakdashAnderson$625K

See the full list for Indiana →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →